
    
      Patients will be randomized to either Stavudine (d4T) + Lamivudine (3TC) + Zidovudine placebo
      or Zidovudine (ZDV) + Lamivudine + Stavudine placebo. Patients whose plasma HIV RNA levels
      remain >= 500 copies/ml after 8 weeks of blinded double combination therapy will have
      indinavir added to their treatment regimen at the week 12 visit.
    
  